| scholarly article | Q13442814 |
| P50 | author | Irina Stepanov | Q42174081 |
| Stephen S. Hecht | Q42174083 | ||
| Lois Biener | Q50142010 | ||
| Dorothy Hatsukami | Q87445426 | ||
| P2093 | author name string | Robin L Bliss | |
| Joni Jensen | |||
| P2860 | cites work | European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health | Q24678392 |
| Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview Survey | Q27497403 | ||
| Review of the evidence that pH is a determinant of nicotine dosage from oral use of smokeless tobacco. | Q32183154 | ||
| New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. | Q33943746 | ||
| Oral spit tobacco: addiction, prevention and treatment | Q34079745 | ||
| Oral Manifestations of Smokeless Tobacco Use | Q34150946 | ||
| The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. | Q34376467 | ||
| Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study | Q34627885 | ||
| Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study | Q34715402 | ||
| Oral tobacco products: preference and effects among smokers. | Q35189459 | ||
| A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers | Q36441730 | ||
| Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers | Q37149026 | ||
| Epidemiological evidence for the role of nitroso compounds in human cancer. | Q38769491 | ||
| Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. | Q39641695 | ||
| Nitrosamines and human cancer: introduction and overview | Q41277698 | ||
| Environmental exposure to N-nitroso compounds (NNOC) and precursors: an overview. | Q41277709 | ||
| Surveillance of smokeless tobacco nicotine, pH, moisture, and unprotonated nicotine content | Q44688196 | ||
| Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines | Q47978013 | ||
| Tobacco‐specific nitrosamines in new tobacco products | Q61207149 | ||
| Prevalence of trial of snus products among adult smokers | Q83433812 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Camelus | Q7375 |
| P304 | page(s) | 1241-1245 | |
| P577 | publication date | 2012-01-17 | |
| P1433 | published in | Nicotine and Tobacco Research | Q15762854 |
| P1476 | title | Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of Camel Snus and Marlboro Snus | |
| P478 | volume | 14 |
| Q37151645 | (S)-N'-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats |
| Q35110020 | Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation. |
| Q37637592 | Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit: a pilot randomized clinical trial |
| Q46907405 | Characteristics of "American snus" and Swedish snus products for sale in Massachusetts, USA. |
| Q45070774 | Consortium on Methods Evaluating Tobacco: Research Tools to Inform FDA Regulation of Snus. |
| Q38805501 | FDA's misplaced priorities: premarket review under the Family Smoking Prevention and Tobacco Control Act. |
| Q42697549 | Menthol decreases oral nicotine aversion in C57BL/6 mice through a TRPM8-dependent mechanism |
| Q33949778 | Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch |
| Q45044780 | Naturalistic assessment of demand for cigarettes, snus, and nicotine gum. |
Search more.